Pan American Health Organization
Regional Office of the World Health Organization

# SURINAME

## Demographic and Socioeconomic Data

| | |
|---|---|
| Total population (thousands)(2012) | 535 |
| Annual births average (thousands) (2012) | 9.6 |
| Women of childbearing age (thousands) (2012) | 140.0 |
| Gross national income (US$ per capita) | |
| Current value (2012) | 8,480 |
| Infant Mortality Rate (2011) | 15.1 |
| Population below int'l poverty line (%)() | ... |
| National health expenditure as a % of GDP | |
| Public expenditure (%)(2011) | ... |
| Private expenditure (%)(2012) | 0.9 |

*Source:* United Nations Population Division ; US Bureau of the Census; The World Bank; and WHO. 2013 or last available year.




***For more information:***

- PAHO country profile: http://www.paho.org/english/dd/ais/cp_740.htm
- WHO Immunization profile: http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm
- GAVI country profile: not applicable

## Immunization Coverage, 1995 – 2012




BCG= bacille de Calmette-Guérin (anti-tuberculosis vaccine); DPT3 = third dose of diphtheria-pertussis-tetanus vaccine (as DPT or combination vaccine); OPV3 = third dose of polio vaccine
MMR = first dose of measles, mumps and rubella vaccine; MMR2 = second dose of measles, mumps and rubella vaccine; Pentavalent = combination vaccine DPT-Hib-HepB

## Immunization Schedule, 2012

| | | | | | |
|---|---|---|---|---|---|
| **BCG** | NA | | | | |
| **OPV** | 2m | 4m | 6m | 18m | 4y |
| **DTP** | | | | 18m | 4y |
| **DTP-Hib-HepB** | 2m | 4m | 6m | | |

| | | |
|---|---|---|
| **Hepatitis B** | NB | risk groups |
| **MMR** | 13-23m | 4y |
| **dT** | 7y+; pregnant women | |
| **Yellow fever** | 1y* | |
| **Influenza** | 6m-2y; chronic disease; adults at risk groups | |

**NA:** not applicable; **NB:** newborn; **m**-month; **y**-year

## Morbidity Data













## Surveillance Indicators, 2012

| Acute Flaccid Paralysis (AFP) - CAREC | Country | Expected |
|---|---|---|
| Number of cases | 5 | |
| AFP rate per 100,000 children aged <15 years | 0.25 | 1.0 |
| % of cases investigated <48 hours | 80 | 80 |
| % of cases with 1 sample collected within 14 days of Onset | 40 | 80 |
| % of sites reporting | 77 | 80 |

| Measles/Rubella - CAREC | Country | Expected |
|---|---|---|
| Number of suspect cases | 554 | |
| % of sites reporting weekly | 83 | 80 |
| % of cases with adequate investigation | 86 | 80 |
| % of cases with adequate sample | 96 | 80 |
| % of samples arriving in lab ≤5 days | 26 | 80 |
| % of results received from lab ≤4 days | 96 | 80 |

*Source*: PESS, MESS, and country reports, FGL-IM, PAHO.

## Highlights:

- Suriname conducted a follow-up campaign for measles and rubella in 2005 and had included a second dose of MMR vaccine into the routine schedule. However, this was discontinued. A follow-up campaign is highly recommended
- Yellow fever vaccination is given in the Hinterlands, but its nationwide expansion is expected
- There is good coordination on immunization with bordering countries, especially during Vaccination Week in the Americas
- Suriname conducted a Data Quality Self-Assessment in early 2009
- Seasonal influenza was not used in the country, but it was used in 2009 in preparation to pandemic vaccination
- Suriname purchased and received donations of the H1N1 vaccine. As of the end of August, around 25,000 doses had been administered
- All vaccines are procured with national funds. Introducing new vaccines will have a significant impact on the EPI budget